Soluble Therapeutics Acquired by CytoBioscience more

Young Living Essential Oils Partners with TFS Sandalwood Farms more

Beaufort Memorial Using Xenex Germ-Zapping Robot to Destroy Pathogens That Can Cause Hospital-Acquired Infections more

DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology more

Cartersville Medical Center Unveils Xenex Germ-Zapping Robot more

DNAtrix enters into license agreement with University of Florida to develop new oncolytic virus platform more

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform more

Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian Sandalwood Oil (EISO) for the Treatment of Psoriasis is Presented at International Conference more

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD) more

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA more

Robotics: Germ-Zappers Are Saving Lives more

DHR first in RGV with xenon UV disinfection systems more

neoSurgical® Announces CE Mark Approval of the neoClose® Laparoscopic Port Closure Device more

Germ-zapping robot named 'Gronk' helped kill MRSA at Mass. high school more

Doctors Hospital at Renaissance is First in Rio Grande Valley to Deploy Xenex Germ-Zapping Robots more

Bio2 Medical's Angel Catheter successfully placed in first two patients more

Cardiovate Develops First Bioabsorbable Vascular Graft more

Funding San Antonio’s Biotech Ecosystem more

A biotech groups to share in major military contract to manufacture stem cells more

Robot disinfecting rooms at Life Line Hospital in Wintersville more

Life Line Hospital is the First Long Term Acute Care Hospital in Ohio to Enhance Patient Safety by Deploying a Xenex Germ-Zapping Robot more

Robots show Marin, Sonoma hospitals the light on disinfection more

Santalis Pharmaceuticals Announces Issuance of Patent for the Use of Sandalwood Oil to Treat Cancers more

Santalis Pharmaceuticals Initiates a Phase 2 Study of Mild, Moderate and Severe Atopic Dermatitis - Enrolls First Patient Into Its Australian Clinical Trial Site more

With Scaffold for Regenerating Arteries, Cardiovate Raises $350,000 more

Bluegrass Vascular Secures CE Mark Approval and Announces Successful Commercial Use of The Surfacer® Inside-Out® Access Catheter System more

Bio2 Medical® Closes on $3 Million of Venture Debt Financing more

Tropical Forestry Services prepares for first Indian sandalwood shipment to China more

Bio2 Medical® Announces 510(k) Clearance from the FDA for the Angel® Catheter, the First Ever Prophylactic Use Indication for a Medical Device for Pulmonary Embolism more

International perfumery competition winner tours Indian sandalwood plantations in the Kimberley more

SA biotech firm drawing global interest year after moving from Germany more

TFS Corporation makes bond offer more

New robot system at USC Verdugo Hills Hospital uses UV light to disinfect hospital rooms more

DNAtrix wins $2 million FDA grant for cancer immunotherapy more

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401 more

TFS Corporation - July 2016 Update more

StemBioSys reaches European distribution agreement for its products more

BRIEF-Diamyd Medical: Cellaviva appointed European distributor for StemBioSys more

DNAtrix Receives European Medicines Agency PRIME Designation more

DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma more

Australia forestry company TFS Corp gets two ratings upgrades more

Tour of Texas: Valence, Stellarray, Flux Farms, A&M, StemBioSys more

StemBioSys reaches distribution agreement for its products in South Korea more

Camden Clark Medical Center Introduces Newest Xenex Germ-Zapping Robot more

MPR Client Innovative Trauma Care Wins Gold at 2016 Medical Design Excellence Awards more

Santalis Pharmaceuticals Announces Positive Results From a Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation for the Treatment of Mild-to-Moderate Plaque Psoriasis more

Texas among top states in foreign investments more

How Your Family Drives Business Decisions more

StemBioSys enters distribution agreement for its products in Japan more

San Antonio biotech firm takes big step toward global expansion more

Vidant Edgecombe Hospital adds Xenex Germ-Zapping Robot to reduce HAIs more

This hospital spent $300,000 on giant, superbug-killing robots more

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis more

SA biotech company backing fed stem cell bill to cut red tape from regulatory pathway more

Bexar County added 4,350 jobs last year, study says more

Springfield Clinic unveils Xenex Germ-Zapping Robot for infection control more

San Antonio venture capital funding fell last year more

neoSurgical Limited Expands Indications For neoClose Device more

Bio2 Medical Closes Series D Preferred Stock more

TFS undertakes $60 million placement more

Bluegrass Vascular Technologies’ catheter system used on first patient more

Cytocentrics refunds $100,000 in economic development funds to city more

Bluegrass Vascular Technologies Announces First Clinical Use of the Surfacer® Inside-Out® Access Catheter System in Europe. more

Long-term acute care facility in California implements Xenex germ-zapping robot more

Robotic housekeeper disinfects the rooms at Modesto hospital more

Aerin Medical raises $16.7M, adds new board members more

Brokers Sniff Sweet Potential In TFS Corp more

East Indian sandalwood oil (EISO) is the key ingredient in these grooming products for dogs more

Santalis Pharmaceuticals Completes the Spin-Off of Roxy’s Remedies Inc. more

TFS Corporation - January 2016 Update more

DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation more

Strategic partnering deal with Cytocentrics more

Cytocentrics CEO: San Antonio to get big boost from new deal more

GhostBuster the Lab Mix Reviews Roxy’s Remedies Pure Relief Spray Gel more

Avera McKennan Addresses Patient Safety with Germ-Zapping Robots more

Santalis Pharmaceuticals Announces Positive Results from a Study of Pediatric Patients with Eczema (Atopic Dermatitis) Treated with the Santalia™ AD Over the Counter Therapy Regimen

SAN ANTONIO--(BUSINESS WIRE)--4th bullet of release issued February 22, 2016 should read: 68% of patients achieved an IGA score of "much improved" or “very much improved" with a minimum 2-grade improvement after eight weeks of treatment (instead of "after four weeks of treatment").

Santalis Pharmaceuticals today announced positive preliminary results from its expanded study of its Santalia™ AD product regimen (serum, cleanser and bubble bath). The Santalia™ AD OTC products all contain East Indian sandalwood oil (EISO) and colloidal oatmeal to treat the symptoms of pediatric eczema (atopic dermatitis). EISO has been demonstrated to inhibit a broad range of inflammatory pathways thought to underlie this skin condition, as well as many pathogens associated with secondary infections of eczema, such as Staphlococcus aureus (“staph”). The results of this study show Santalia™ AD to be safe, well tolerated, and efficacious for patients aged between 3 months to 12 years who have mild, moderate or severe eczema affecting a large percentage of their body surface area. The treatment regimen comprised a twice-daily application of the serum and cleanser to the affected areas and a bubble bath used three times a week.

“The results of this study are very encouraging. The Santalia™ AD kit had a significant impact on the quality of life of these patients and their parents. The results seen were better than had been previously achieved by these patients from the use of other topical treatments, including both over-the-counter and prescription drugs. This improvement is further evidenced by the number of parents asking to continue using the product kit after the study had finished. The Santalia™ AD OTC kit should be the first choice for parents before visiting the doctor’s office,” said John Browning, M.D., Assistant Professor of Pediatrics and Dermatology at Baylor College of Medicine and Chief of Dermatology at Children’s Hospital of San Antonio.

“This shows clearly the significant benefit of Santalia™ AD, a combination of EISO and colloidal oatmeal, in the OTC treatment of young children, where the choice of effective and safe products is limited,” said Paul Castella, Chief Executive Officer of Santalis Pharmaceuticals. “This OTC study provides additional support for our EISO-based prescription drug program for eczema, which we intend to start later this year with the initiation of placebo-controlled clinical studies.”
The results from the study have been submitted for publication and the Santalia™ AD OTC kit should be available for distribution at the start of 2017.

Santalia™ AD Regimen
The single-center, open-label study enrolled 25 patients, ages 3 months to 12 years with mild, moderate or severe atopic dermatitis with a mean beginning Eczema Area and Severity Index (EASI) score of 11.1 (moderate). Treatable atopic dermatitis, for this study, was defined as an EASI score ≥5 but ≤ 52. The EASI scoring system is a validated investigator-assessed instrument, which measures the severity of clinical attributes of atopic dermatitis in patients. Patients (or their caregivers) were instructed to apply the Santalia™ AD Regimen cleanser and cream twice daily for 60 days and bubble bath at least three times weekly.

Safety, tolerability and efficacy endpoints were all included as a part of this study. Safety evaluation included an assessment of safety based on the frequency and severity of systemic and local adverse events (AEs) when the Santalia™ AD Regimen is applied to pediatric and adolescent patients with atopic dermatitis for up to 60 days. Tolerability was determined by the number and percentage of patients reporting burning, itching, scaling, erythema, dryness, or stinging of the treatment area(s). Primary efficacy was determined by the percentage of patients who had at least a 25% improvement in the EASI score at any time point during the 60 days of therapy.

Secondary efficacy endpoints included patients having a >25%-50% improvement in EASI score at Visit 6, >51% improvement in EASI score at Visit 6, and descriptive assessments of improvement in the severity and extent of disease based on the Investigator Global Assessment at Visit 6 as well as a comparison of Baseline and Visit 6 Children’s Dermatitis Life Quality Index (CDLQ) or Infant Dermatitis Quality of Life Index Questionnaire (IDQoL). The Investigator Global Assessment is a 5-measure scale, from “worse” to “very much improved,” recording the change in a patient’s atopic dermatitis at each visit compared to the status of the condition at baseline.

Efficacy

22 out of 25 patients completed the study

82% (18/22) of patients met the primary efficacy endpoint (a 25% reduction in their EASI score)

91% (20/22) of patients experienced a reduction in their EASI score

68% of patients achieved an IGA score of "much improved" or “very much improved" with a minimum 2-grade improvement after eight weeks of treatment

61.9% of patients achieved an IGA score of "much improved" or “very much improved" with a minimum 2-grade improvement after four weeks of treatment

Patients demonstrated an average 60% reduction in EASI score over Baseline

In patient diary responses, the aggregate score for all diary responses went from 0 at study commencement to 3.1 (much Improvement) in 8 weeks

74.7% of respondents reported an aggregate score of 3 (much improvement) or 4 (very much improved) at study end

78.9% reported a reduction in both redness and an improvement in skin texture of the treated area and 73.7% reported an improvement in pain or irritation of the treatment area

Safety and Tolerability
The Santalia™ AD Regimen was generally safe and well-tolerated with no AEs found to be possibly, probably or definitely related to the study drug.

About Eczema/Atopic Dermatitis
Eczema/atopic dermatitis is a chronic skin condition involving inflammation and itching. The rash is characterized by red, oozing patches and thickening of the skin. Rubbing and scratching can lead to skin damage and secondary bacterial infections. Approximately 18 to 25 million people in the United States are believed to suffer from atopic dermatitis, with 80% to 90% having mild or moderate disease. It is estimated that the incidence of the disease amongst infants and children in the US is between 8% and 18%. Though most common in the pediatric population, about half of childhood cases carry over into adulthood. There is currently no cure for atopic dermatitis and current therapies are primarily palliative, focused on reduction of symptoms (redness, itching, etc.). Moisturizers, anti-inflammatory drugs, phototherapy and other approaches are often used. Long-term use of many of the current treatments is often not effective or can lead to complicating side effects.

About Santalis Pharmaceuticals
Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and are developing scientifically and clinically validated over the counter and prescription products that utilize TFS’ cultivated, sustainable, pharmaceutical-grade East Indian Sandalwood Oil. Santalis’ product development programs are focused in oral health and dermatology, where EISO’s well documented safety and anti-infective, anti-proliferative and anti-inflammatory properties are well suited to a number of prevalent and under­served conditions (such as acne, eczema, psoriasis, oral mucositis, onychomycosis, HPV skin warts and Molluscum Contagiosum). In addition to an eczema program study, Santalis has ongoing Phase 2 studies in pediatric Molluscum contagiosum, oral mucositis, and psoriasis, and is preparing to initiate a Phase 3 study for pediatric HPV skin warts.

About East Indian Sandalwood
Indian sandalwood has a history as a tradeable commodity spanning thousands of years, but is now endangered due to the illegal harvest of wild trees throughout the world. As a result, Indian sandalwood is the world’s most expensive tropical hardwood. Indian sandalwood oil is a globally important ingredient in fine fragrances, cosmetics and toiletries, Indian consumer products and is used for traditional medicinal purposes (Ayurvedic and Chinese medicine). The wood is used for high quality carvings and artefacts and religious worship in the Hindu and Buddhist faiths. The global pharmaceutical market has the potential to be a significant consumer of Indian sandalwood.

Contacts
Santalis Pharmaceuticals, Inc.
Jim Traa, CBO, 210-399-2318
jim@santalispharma.com

Source: http://www.businesswire.com back

Santalis announces positive results for pediatric atopic dermatitis treatment more

Here’s why the TFS Corporation Limited share price soared 28% today more

Cytocentrics gaining traction in San Antonio more

The Drugstore Acne Fighters Dermatologists Swear By more

neoSurgical® Begins Postmarket Surveillance Study more

Santalis Announces First Subject Enrolled in Phase 2 Trial more

BiO2 Medical Reports Positive Advancement of the Series D Round of Funding more

Germany’s Axiogenesis to collaborate with new San Antonio biotech company more